|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma.
|
18462259 |
2009 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
|
20498063 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclosed also in non malignant thyroid lesions and their biological significance is debated.
|
21048359 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclosed also in non malignant thyroid lesions and their biological significance is debated.
|
21048359 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
|
20498063 |
2010 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation and progression and the evaluation of inhibitors of oncogenic BRAF signaling.
|
21512141 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.
|
21185263 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we have shown that PLX4720 preferentially inhibits migration and invasion of B-Raf(V600E) thyroid cancer cells and tumor aggressiveness.
|
21355020 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we have shown that PLX4720 preferentially inhibits migration and invasion of B-Raf(V600E) thyroid cancer cells and tumor aggressiveness.
|
21355020 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation and progression and the evaluation of inhibitors of oncogenic BRAF signaling.
|
21512141 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study investigated the therapeutic potential of a BRAF(V600E)-selective inhibitor, PLX4032 (RG7204), for thyroid cancer by examining its effects on the MAP kinase signaling and proliferation of 10 thyroid cancer cell lines with wild-type BRAF or BRAF(T1799A) mutation.
|
21185263 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Polymerase chain reaction was used to amplify exon 15 of the BRAF gene from paraffin-embedded thyroid tumor specimens, followed by direct sequencing to detect the BRAF(V600E) mutation.
|
22190222 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Both the metastasis and the primary thyroid tumor are positive for BRAF(V600E) mutation.
|
22435913 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation using thyroid cancer tissue from 424 patients who underwent thyroidectomy with cervical lymph node dissection.
|
21803329 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study tests the prevalence of BRAF (V600E) mutation in thyroid cancer patients in Indian subcontinental population.
|
22105775 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation analysis, indicating that the screening for BRAF mutation in FNAB samples has a relevant diagnostic potential.
|
22535974 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel avenues for thyroid cancer treatment.
|
22858857 |
2012 |